Company Overview - Nasus Pharma Ltd. is a clinical-stage pharmaceutical company focused on developing innovative intranasal products for emergency medical conditions [3] - The company is developing NS002, an intranasal powder Epinephrine product candidate, as a needle-free alternative to traditional Epinephrine autoinjectors for anaphylaxis treatment [3] - Nasus Pharma utilizes proprietary powder-based intranasal (PBI) technology designed for rapid and reliable drug delivery, leveraging the nasal cavity's vascular network for quick absorption [3] Conference Participation - Company management will present at the H.C. Wainwright 27th Annual Global Investment Conference [1] - Management will be available for one-on-one meetings during the conference, and interested investors are encouraged to contact their representatives at sponsoring institutions [2] - The company presentation is scheduled for September 5, 2025, from 07:00 to 07:30 a.m. ET, with CEO Dan Teleman as the presenter [4]

Core Insights - Nasus Pharma Ltd. has successfully listed on the New York Stock Exchange and celebrated this milestone by ringing the Closing Bell on August 25, 2025, highlighting its commitment to transforming emergency medicine through innovative intranasal therapies [1][2][3] Company Overview - Nasus Pharma is a clinical-stage pharmaceutical company focused on developing intranasal powder products aimed at treating acute medical conditions, particularly severe allergic reactions and anaphylaxis [4] - The company's lead product candidate, NS002, is an intranasal powder formulation of Epinephrine, designed as a needle-free alternative to traditional Epinephrine autoinjectors [4] Technology and Innovation - The proprietary powder-based intranasal (PBI) technology developed by Nasus Pharma is intended for rapid and reliable drug delivery, utilizing the nasal cavity's vascular network for quick absorption [4] - The PBI formulation employs uniform spherical powder particles to ensure broad dispersion and potentially faster absorption compared to liquid-based nasal products [4] Leadership and Vision - The CEO of Nasus Pharma, Dan Teleman, emphasized the company's dedication to innovation and its mission to develop life-saving treatments that are easy to use and accessible during emergencies [3]

Core Viewpoint - Nasus Pharma Ltd. has successfully closed its initial public offering (IPO) of 1,250,000 ordinary shares at a price of $8.00 per share, raising gross proceeds of $10 million, which will be used to advance its intranasal Epinephrine program and for general corporate purposes [1][2]. Group 1: IPO Details - The IPO consisted of 1,250,000 ordinary shares priced at $8.00 each, resulting in gross proceeds of $10 million before expenses [1]. - Shares began trading on the NYSE American LLC under the ticker symbol "NSRX" on August 13, 2025 [1]. - Underwriters have an option to purchase an additional 187,500 shares within 45 days at the IPO price [1]. Group 2: Use of Proceeds - The net proceeds from the IPO will primarily fund the development of the intranasal Epinephrine program, including manufacturing scale-up and additional Phase 2 studies [2]. - Remaining funds will be allocated for general and administrative purposes, including working capital and capital expenditures [2]. Group 3: Company Overview - Nasus Pharma is a clinical-stage pharmaceutical company focused on developing intranasal powder products for acute medical conditions [5]. - The company's lead product candidate, NS002, is an intranasal powder formulation of Epinephrine designed as a needle-free alternative for anaphylaxis treatment [5]. - The proprietary powder-based intranasal (PBI) technology aims for rapid and reliable drug delivery, utilizing the nasal cavity's vascular network for quick absorption [5].

Core Viewpoint - Nasus Pharma Ltd. has successfully priced its initial public offering (IPO) of 1,250,000 ordinary shares at $8.00 per share, aiming for gross proceeds of $10 million before expenses [1][4]. Group 1: IPO Details - The IPO consists of 1,250,000 ordinary shares priced at $8.00 each, targeting total gross proceeds of $10 million [1]. - An additional option for underwriters allows them to purchase up to 187,500 ordinary shares within 45 days to cover over-allotments [1]. - The shares are approved for listing on NYSE American under the ticker symbol "NSRX," with trading expected to commence on August 13, 2025 [3]. Group 2: Use of Proceeds - The net proceeds from the IPO will primarily fund the development of the intranasal Epinephrine program, including manufacturing scale-up and additional Phase 2 studies [2]. - Remaining funds will be allocated for general corporate purposes, including working capital and capital expenditures [2]. Group 3: Company Overview - Nasus Pharma is a clinical-stage pharmaceutical company focused on developing innovative intranasal products for emergency medical conditions [6]. - The company's lead product candidate, NS002, is an intranasal powder formulation of Epinephrine designed as a needle-free alternative for anaphylaxis treatment [6]. - The proprietary powder-based intranasal (PBI) technology aims for rapid and reliable drug delivery, utilizing the nasal cavity's vascular network for quick absorption [6].